ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Anti-Inflammatory Mechanisms of Selenium Nanosheets in Ulcerative Colitis: Protein Corona, GP130 Interaction, and Transcriptomic Profile.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- NIR-Triggered On-Demand Synergistic Therapy for Multidrug-Resistant Bacterial Infections Via a Smart Phase-Transition Hydrogel.Advanced healthcare materials · 2026Article
- Gut microenvironment-responsive copper selenide/disulfiram/eudragitJournal of nanobiotechnology · 2026Article
- Anti-Inflammatory Mechanisms of Selenium Nanosheets in Ulcerative Colitis: Protein Corona, GP130 Interaction, and Transcriptomic Profile.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ulcerative colitis (UC) is a complex inflammatory bowel disease characterized by multiple factors. Alleviating inflammation is the primary therapeutic approach. However, currently employed anti-inflammatory treatments have limited efficacy and cause side effects. Safer, more effective therapies are needed. Selenium nanosheets (SeNSs) are biocompatible, anti-inflammatory, and low-toxicity nanomaterials with high surface areas and abundant active sites, making them potential therapeutic agents for UC. This study indicates that SeNSs can interact with macrophages and adhere to their cell membranes, significantly increasing their internalization into cells. Proteomic analysis reveals that the main components of the SeNS protein corona are proteins involved in cell proliferation and migration, including those associated with the AKT/PI3K and NF-κB signaling pathways. SeNSs hydrophobically interact with GP130, inhibiting its expression. This interaction downregulates the proteins involved in the aforementioned pathways. In addition, a transcriptomic analysis confirms that SeNSs inhibit apoptosis, cytokine-cytokine receptor interactions, and the chemokine and TNF signaling pathways. In dextran sulfate sodium (DSS)-induced UC model mice, SeNSs significantly decrease IL-1β, IL-6, and TNF-α levels, alleviate tissue damage, and lower the disease activity index. These findings suggest that SeNSs can be a safe and effective treatment strategy for UC, offering a novel approach for managing inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.